<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T03:28:01Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/30408" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/30408</identifier><datestamp>2026-09-24T03:06:16Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Sadeghirad, Behnam</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Moradi, Sara</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Health Research Methodology</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2024-10-11T18:16:36Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2024-10-11T18:16:36Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2024</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/30408</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/16556</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Background: Chronic non-cancer pain (CNCP) is a prevalent condition, imposing significant burden on healthcare systems. Ketamine is suggested as a potential intervention for CNCP management. We conducted a systematic review and network meta-analysis to assess ketamine's effects in adults with CNCP.&#xd;
Methods: We searched Medline, Embase, CINAHL, and Cochrane CENTRAL up to January-2024 for randomized trials involving adults with CNCP, comparing ketamine with placebo, usual care, or other interventions. Reviewers independently assessed trial eligibility, extracted data, and evaluated risk-of-bias using the Cochrane tool. A random-effects network meta-analysis was performed. We assessed evidence certainty using GRADE.&#xd;
Results: We included 38 trials, with the following comparisons made between ketamine and placebo, using 0-10 VAS: At &lt;30 minutes, ketamine may slightly reduce pain intensity (-1.32, 95% CI: [-1.73 to -0.90], low-certainty). At 1-3 hours follow-up, ketamine may slightly reduce pain intensity (MD: -1.25, (95% CI: [-1.76 to -0.74], low-certainty). At 3-to-7 days follow-up, ketamine may have little to no effect on pain intensity (MD: -1.34, 95% CI: [-2.29 to -0.39], low-certainty). At 3-to-5 weeks follow-up, ketamine likely results in no pain reduction (MD: -0.99, 95% CI: [-2.00 to 0.03], moderate-certainty). At beyond 5 weeks the evidence about ketamine pain reduction is very uncertain (MD: -1.09, 95% CI: [-1.86 to -0.32], very-low-certainty). Ketamine had no effect on physical functioning. Compared to placebo, ketamine may result in a slight increase in the risk of gastrointestinal adverse events (RR: 3.97, 95% CI: [2.18 to 7.22], RD: 12%, 95% CI: [5% to 25%], very-low-certainty), an increase in risk of dizziness (RR: 3.66, 95% CI: [1.25 to 10.74], RD: 11%, 95% CI: [1% to 40%], low-certainty), may increase the risk of fatigue, somnolence, and sedation (RR: 2.89, 95% CI: [1.84 to 4.53], RD: 27%, 95% CI: [12% to 50%], low-certainty), may increase of the incidence of dissociative symptoms (RR: 4.22, 95% CI: [2.20 to 8.10], RD: 17%, 95% CI: [6% to 37%], low-&#xd;
M.Sc. Thesis – Sara Moradi; McMaster University – Health Research Methodology&#xd;
iv&#xd;
certainty), and it may result in a slight increase in the risk of visual impairment (RR: 10.21, 95% CI: [2.86 to 36.42], RD: not evaluable, very-low-certainty). We did not have enough data to pool effect estimates for other outcomes.&#xd;
Conclusion: Ketamine may provide small but important benefit in CNCP patients at immediate-to-short follow-up, but it probably has little to no benefit at beyond 3-weeks. Ketamine is likely to provide similar benefits compared to alternative active interventions; however, these benefits may be associated with important side-effects.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">ketamine</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">chronic pain</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">CNCP</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">meta-analysis</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Benefits and harms of Ketamine for management of chronic non-cancer pain</dim:field>
   <dim:field mdschema="dc" element="title" qualifier="alternative" lang="en_US">Comparative effectiveness of Ketamine for management of chronic non-cancer pain: A systematic review and network meta-analysis of randomized controlled trials</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>